News

The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.

The agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries.

Researchers have now found that subjects who underwent cataract surgery had nearly 30% lower risk of developing dementia from any cause compared with those who did not.

Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg and 0.3 mg formulations compared with vehicle hydrogel insert.

The approval will allow LensGen to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the United States.

Omidria will become a key product in Rayner's ophthalmology franchise, which includes intraocular lenses, ophthalmic viscoelastic devices and dry eye treatments.

Save the dates for this virtual interactive conference featuring top US ophthalmologists

Successful treatment options can offer hope for patients with inherited disease.

Investigators conducted a retrospective consecutive study in which they compared the outcomes using this approach with the results achieved with local anesthesia alone during cataract surgery.

This model can restore visual function and provide good intermediate and near vision in both photopic and mesopic conditions.

According to Yvonne Ou, MD, the test can objectively detect relative changes in the on and off pathways.

Approaches include anti-vascular endothelial growth factor agents, fine needle diathermy, and corneal collagen crosslinking.

Performing cataract surgery on young patients can be a challenge, and the evolving technology can be used in cataract surgery for young children.

The company's AI-enabled mobile telemedicine platform helps clinicians capture retinal images and screen for vision-threatening eye diseases, such as diabetic retinopathy, glaucoma and age-related macular degeneration.

The company’s re:Vive technology features 6 vision diagnostic exams, supported by 5 reimbursable CPT codes in 1 wearable solution.

Investigators believe the therapy could prove to be an option for the treatment of other retinopathies.

Investigators set out to better define therapeutic options for controlling the inflammatory response and reducing the risk of pseudophakic cystoid macular edema after cataract surgery.

An experience at the grocery store serves as a reminder of the importance of fundraising for eye research.

Oxymetazoline hydrochloride has been recognized by the publication as a winner of its Best of Beauty Breakthrough Award.

Sotrovimab, a monoclonal antibody, appears to reduce the risk of progression of mild-to-moderate cases of COVID-19 in patients at high risk of progression.

The agreement also includes an exclusive option for Novartis to acquire Kedalion and its AcuStream technology. No financial terms were disclosed.

The Children’s Vision Equity Alliance was created to improve acces in children’s vision and eye health, working to advance equity in children’s vision and eye health through education, access, policies, and partnerships.

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

A web app-based personalized music intervention before cataract surgery may lower anxiety levels or reduce the need for sedative medication.

CellSight researchers at the Sue Anschutz-Rodgers Eye Center were published for a discovery that could lead to early diagnosis and intervention of dry age-related macular degeneration.

Veeral Sheth, MD, presents research finding faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

Gareth Lema, MD, PhD, spotlights a treatment could provide benefits for patients with central retinal artery occlusion.